Arthneeti
All Q1 FY26 results →
NA

Novartis AG

Q1 FY26Pharmaceuticals

Novartis AG Q1 FY26 Results — Earnings Call Analysis

Q1 FY26 earnings call: what management said on revenue, margins and capex.

Price₹151
Market cap₹2.9L Cr
P/E21.6
Updated29 May 2026
Read4 min read

What the Q1 FY26 call signalled

1 of 3 strong

RevenueSlow growth
MarginMargins steady
CapexCapex planned

The short version

- Novartis expects low single-digit sales growth in 2026 despite significant patent expiries and generic competition in the U.S. - Novartis expects 5% to 6% sales CAGR from 2025 to 2030, despite patent expiries and U.S.

From Novartis AG's Q1 FY26 earnings-call transcript · updated 29 May 2026.

Revenue & Sales Performance

Slow growth
  • Novartis expects low single-digit sales growth in 2026 despite significant patent expiries and generic competition in the U.S. in the first half of 2026.
  • Mid-single-digit sales growth is expected in the second half of 2026, leading to a full-year low single-digit growth overall.
  • The company projects a 5% to 6% compounded annual growth rate (CAGR) in sales from 2025 through 2030, including impacts from generic entries and U.S. MFN agreements.
  • Growth is anticipated to be driven by priority brands, pipeline assets (e.g., lanalumab, Pluvicto, pelacarsen, Avidity assets), and global expansions such as Leqvio in China.

2 more points from Novartis AG's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Novartis AG said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Novartis invested over $10 billion in R&D in 2025, an 8% increase compared to the prior year, focusing on strengthening key platforms and pipelines across their four therapeutic areas.
  • The company completed a $15 billion share buyback program in early July 2025 and launched a new up to $10 billion share buyback program targeted for completion by the end of 2027, with approximately $7.7 billion remaining to be executed.
  • Novartis announced 4 acquisitions and 10 licensing deals in 2025, focusing on cardiovascular, immunology, neuroscience, and oncology assets, aiming to build and diversify their pipeline.

2 more points from Novartis AG's call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Novartis AG said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Relevant points related to business outlook and growth include: - Novartis expects a 5% to 6% compound annual growth rate (CAGR) in sales from 2025 to 2030. - Anticipation of strong volume growth from priority brands throughout 2026 despite a challenging first half due to prior year base effects. - Full year 2026 sales guidance is low single digit growth. - Pipeline assets including Rhapsido, ianalumab, pelacarsen, and Avidity programs are expected to drive future growth.

2 more points from Novartis AG's call on order book

Create a free account to keep reading this call

Continue your research

Others in Pharmaceuticals this season

  • Haleon plc (Q1 FY26)

    Haleon plc Q1 FY26 quarterly results analysis. Organic sales growth guidance for 2026 is 3% to 5%, signaling some sequential acceleration from 3% in 2025. Marke

  • Takeda Pharmaceutical Company Limited (Q1 FY26)

    Takeda Pharmaceutical Company Limited Q1 FY26 quarterly results analysis. Growth in plasma-derived therapies (PDT) expected to be mid-single-digit growth for th

  • Novo Nordisk A/S (Q1 FY26)

    Novo Nordisk A/S Q1 FY26 quarterly results analysis. 2026 sales growth is expected to be negative, with adjusted sales growth projected at -5% to -13% at consta

  • Sanofi (Q1 FY26)

    Sanofi Q1 FY26 quarterly results analysis. For 2026, Sanofi expects sales to grow by a high single-digit percentage and business EPS to grow slightly faster tha

Compare:vs AstraZeneca PLCvs Johnson & Johnsonvs Novo Nordisk A/S

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Novartis AG and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Novartis AG Q1 FY26 results?

- Novartis expects low single-digit sales growth in 2026 despite significant patent expiries and generic competition in the U.S. - Novartis expects 5% to 6% sales CAGR from 2025 to 2030, despite patent expiries and U.S.

What is Novartis AG share price analysis?

Novartis AG currently shows a neutral. The stock trades at a P/E of 21.6 with a market cap of $288,894. Investors should review the full earnings analysis for detailed insights.

Is Novartis AG planning capital expenditure?

- Novartis invested over $10 billion in R&D in 2025, an 8% increase compared to the prior year, focusing on strengthening key platforms and pipelines across their four therapeutic areas.

Keep Novartis AG on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.